Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 311 | 629 | 1,269 | 1,061 | 986 |
| Gross Profit | 311 | 629 | 1,269 | 1,061 | 986 |
| Operating Expenses | 19,554 | 21,192 | 21,400 | 27,475 | 23,032 |
| Operating Income | -19,243 | -20,563 | -20,131 | -26,414 | -22,046 |
| Other Income | 62,374 | -61,560 | 963 | 31,664 | -12,793 |
| Pre-tax Income | 43,131 | -82,123 | -19,168 | 5,250 | -34,839 |
| Income Tax | 43 | 27 | 91 | 189 | 24 |
| Net Income Continuous | 43,088 | -82,150 | -19,259 | 5,061 | -34,863 |
| Net Income | $43,088 | $-82,150 | $-19,259 | $5,061 | $-34,863 |
| EPS Basic Total Ops | 5.12 | -13.10 | -3.07 | 0.81 | -5.58 |
| EPS Basic Continuous Ops | 5.12 | -13.10 | -3.07 | 0.81 | -5.58 |
| EPS Diluted Total Ops | -2.11 | -13.10 | -3.07 | 0.81 | -5.58 |
| EPS Diluted Continuous Ops | 4.95 | -13.10 | -3.07 | 0.81 | -5.58 |
| EPS Diluted Before Non-Recurring Items | -2.11 | -3.41 | -3.07 | 0.75 | N/A |
| EBITDA(a) | $-19,186 | $-21,859 | $-19,939 | $-26,656 | $-21,456 |